<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520091</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0203</org_study_id>
    <secondary_id>CDR0000561610</secondary_id>
    <nct_id>NCT00520091</nct_id>
    <nct_alias>NCT00280124</nct_alias>
  </id_info>
  <brief_title>Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer</brief_title>
  <official_title>A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop&#xD;
      the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving&#xD;
      chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together&#xD;
      with radiation therapy with or without celecoxib works in treating patients with stage II,&#xD;
      stage III, or stage IV esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To measure the rates of cellular apoptosis and proliferation at baseline and during&#xD;
           chemoradiotherapy with and without celecoxib using biopsy samples from patients with&#xD;
           stage II, III, or IV esophageal cancer.&#xD;
&#xD;
        -  To determine if an acceptable rate of pathologic complete remission can be achieved in a&#xD;
           subset of patients with potentially resectable esophageal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the safety of the addition of daily celecoxib to chemoradiotherapy.&#xD;
&#xD;
        -  To estimate the median overall survival in a subset of patients with resectable disease.&#xD;
&#xD;
        -  To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2&#xD;
           (PGE2) in patients with esophageal cancer.&#xD;
&#xD;
        -  To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by&#xD;
           measuring pre- and post-treatment tumor concentrations of PGE2.&#xD;
&#xD;
        -  To quantitate downstream effects of inhibition of COX-2 function in the setting of&#xD;
           treatment with chemotherapy.&#xD;
&#xD;
        -  To measure the radiographic response rate in patients with unresectable esophageal&#xD;
           cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2&#xD;
      treatment groups.&#xD;
&#xD;
        -  Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over&#xD;
           90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy&#xD;
           once daily 5 days a week for 5 weeks beginning on day 43.&#xD;
&#xD;
        -  Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral&#xD;
           celecoxib twice daily beginning 3 days before the initiation of chemotherapy and&#xD;
           continuing until the completion of chemoradiotherapy.&#xD;
&#xD;
      In both groups, patients with potentially resectable disease undergo surgery no more than 12&#xD;
      weeks after completion of chemoradiotherapy.&#xD;
&#xD;
      Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy.&#xD;
      Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion;&#xD;
      apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation;&#xD;
      and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme&#xD;
      immunoassay, TUNEL assay, colorimetric assay, and northern blotting.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of cellular apoptosis and proliferation</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of pathologic complete remission in patients with resectable disease</measure>
    <time_frame>4 years</time_frame>
    <description>To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events</measure>
    <time_frame>30 days post radiation</time_frame>
    <description>Adverse events/toxicity will graded per the CTCAE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival of patients with resectable disease</measure>
    <time_frame>4 years</time_frame>
    <description>Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formation of prostaglandin E2 (PGE2) in tumor tissue</measure>
    <time_frame>12 weeks</time_frame>
    <description>The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Downstream effects of inhibition of cyclooxygenase 2 function</measure>
    <time_frame>12 weeks</time_frame>
    <description>A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test. A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>4 years</time_frame>
    <description>Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy and chemoradiation without celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy and chemoradiation with celecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT- 11</intervention_name>
    <description>65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Cis-diammine-dichloro-platinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery will occur prior to chemoradiation therapy for those patients with resectable disease</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus&#xD;
&#xD;
               -  Lesions including the gastroesophageal junction allowed provided the tumor&#xD;
                  involves less than 2 cm of gastric cardia&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy&#xD;
                  either for preoperative or palliative indications (group 1)&#xD;
&#xD;
                    -  Suitable candidate for bimodality (palliative intent) or trimodality&#xD;
                       (curative intent) therapy&#xD;
&#xD;
               -  Clinical stage II or III disease AND candidate to receive chemoradiotherapy for&#xD;
                  preoperative indication followed by planned esophagectomy or esophagogastrectomy&#xD;
                  (group 2)&#xD;
&#xD;
                    -  Suitable candidate for trimodality (curative intent) therapy&#xD;
&#xD;
          -  No tracheoesophageal fistula on bronchoscopy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months (group 1)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Adequate nutrition&#xD;
&#xD;
          -  WBC ≥ 4,000/μL&#xD;
&#xD;
          -  ANC ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  No other prior or concurrent malignancy other than curatively treated carcinoma in&#xD;
             situ of the cervix; localized prostate cancer that was previously treated with local&#xD;
             therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of&#xD;
             the skin; or superficial transitional cell carcinoma of the bladder&#xD;
&#xD;
               -  Patients who have had a prior malignancy are eligible if they have been free of&#xD;
                  disease for ≥ 5 years&#xD;
&#xD;
          -  No serious medical or psychiatric illnesses that would preclude giving informed&#xD;
             consent or otherwise limit survival to less than 2 years&#xD;
&#xD;
          -  No history of known NSAID-induced gastrointestinal bleeding&#xD;
&#xD;
          -  No current peptic ulcer disease&#xD;
&#xD;
          -  No active coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction or cerebrovascular accident within the past 3 months&#xD;
&#xD;
          -  No history of refractory congestive heart failure or cardiomyopathy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 1 week since prior major surgery (group 1)&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery (group 2)&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
          -  More than 30 days since prior cyclooxygenase-2 inhibitors (selective or&#xD;
             non-selective), including, but not limited to, any of the following:&#xD;
&#xD;
               -  Acetylsalicylic acid (aspirin)&#xD;
&#xD;
               -  Piroxicam&#xD;
&#xD;
               -  Diclofenac&#xD;
&#xD;
               -  Meloxicam&#xD;
&#xD;
               -  Indomethacin&#xD;
&#xD;
               -  Fenoprofen&#xD;
&#xD;
               -  Sulindac&#xD;
&#xD;
               -  Flurbiprofen&#xD;
&#xD;
               -  Tolmetin&#xD;
&#xD;
               -  Ibuprofen&#xD;
&#xD;
               -  Celecoxib&#xD;
&#xD;
               -  Ketoprofen&#xD;
&#xD;
               -  Rofecoxib&#xD;
&#xD;
               -  Ketoprofen ER&#xD;
&#xD;
               -  Valdecoxib&#xD;
&#xD;
               -  Naproxen&#xD;
&#xD;
               -  Meclofenamate&#xD;
&#xD;
               -  Oxaprozin&#xD;
&#xD;
               -  Mefenamic acid&#xD;
&#xD;
               -  Etodolac&#xD;
&#xD;
               -  Nabumetone&#xD;
&#xD;
               -  Ketorolac&#xD;
&#xD;
          -  No concurrent seizure medications&#xD;
&#xD;
          -  No concurrent amifostine or other such agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bert H. O'Neil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>May 16, 2012</last_update_submitted>
  <last_update_submitted_qc>May 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

